Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 9/20 | 0.45 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19739283 | 0.90 | ERBB2 (0.45) | ERBB2PLAULMNAPLGPLAT | |
| SCHEMBL19739221 | 0.90 | ERBB2 (0.37) | ERBB2LMNAGRM4GSK3BDYRK1A | |
| SCHEMBL19637045 | 0.90 | ERBB2 (0.53) | ERBB2TUBB1GRM4 | |
| SCHEMBL30045662 | 0.86 | ERBB2 (0.37) | ERBB2GRM4GSK3BDYRK1A | |
| SCHEMBL17230049 | 0.84 | CYP17A1 (0.40) | PLAUGSK3BDYRK1A | |
| SCHEMBL19614936 | 0.82 | ERBB2 (0.42) | ERBB2LMNAGRM4GSK3BDYRK1A | |
| SCHEMBL19739072 | 0.81 | CYP17A1 (0.41) | ERBB2GSK3BDYRK1A | |
| SCHEMBL26073602 | 0.81 | CYP17A1 (0.43) | GSK3BDYRK1A | |
| SCHEMBL19632862 | 0.80 | ERBB2 (0.44) | ERBB2LMNAGRM4 | |
| SCHEMBL28458723 | 0.80 | CYP17A1 (0.42) | GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475284-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3475284-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Mersana Therapeutics, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223275-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | ERBB2 65/4885PLAU 3684/4885TUBB1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.